Target intelligence / Profile preview

Cytochrome P450 family 27 subfamily B member 1 (CYP27B1) and Cytochrome P450 family 24 subfamily A member 1 (CYP24A1) (CYP27B1 and CYP24A1)

Target
CYP27B1 and CYP24A1
Molecular classification
Enzyme, Cytochrome P450 monooxygenase, Mitochondrial enzyme
01

Overview

Cytochrome P450 family enzymes CYP27B1 and CYP24A1 are key regulators of vitamin D metabolism. - CYP27B1, also known as 25-hydroxyvitamin D(3) 1-alpha-hydroxylase, is a mitochondrial cytochrome P450 monooxygenase that catalyzes the final activation step converting circulating calcifediol [25(OH)D] into its biologically active form, calcitriol [1,25(OH)₂D]. This reaction is crucial for calcium absorption and bone health. Its activity is regulated by parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), calcium, phosphate status, and feedback from calcitriol itself. - CYP24A1, known as Vitamin D(3) 24-hydroxylase, is responsible for initiating the catabolism/inactivation pathway by converting both calcifediol [25(OH)D] and calcitriol [1,25(OH)₂D] into less active metabolites such as 24,25-dihydroxyvitamin D. This process prevents excess accumulation of active vitamin D compounds. Mutations leading to loss-of-function cause elevated serum calcium due to impaired breakdown—manifesting clinically as hypercalcemia or kidney stones—and play a role in chronic kidney disease-mineral bone disorder pathophysiology. Both enzymes are widely expressed beyond classical target tissues like kidney—appearing also in intestine and various extrarenal sites—and their dysregulation has been implicated not only in mineral disorders but also cancer progression through altered local production/degradation of bioactive vitamin Ds within tissues such as breast tumors. Their activities represent important therapeutic targets for diseases involving abnormal mineral homeostasis.

Other names
CYP27B1: 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrialCYP27B1: Vitamin D-activating enzymeCYP24A1: Vitamin D(3) 24-hydroxylaseCYP24A1: Calcidiol 24-hydroxylase
02

Mechanism of action

Drugs targeting these enzymes typically act by: - Inhibiting or enhancing the conversion between inactive/active/inactive forms of vitamin D metabolites. - CYP27B1 catalyzes the activation step from calcifediol to calcitriol. - CYP24A1 catalyzes the inactivation/catabolic steps from active forms to less active/inactive metabolites.

03

Biological functions

Vitamin D metabolism (activation and inactivation)Calcium and phosphorus homeostasisRegulation of mineral balanceFeedback regulation of vitamin D hormone levels
04

Disease associations

Cancer (notably breast cancer)Chronic kidney disease/mineral bone disorder (CKD/MBD)Hypercalcemia, nephrolithiasis, hyperparathyroidism due to genetic mutations or dysregulation of these enzymes
05

Safety considerations

Risk of hypercalcemia when inhibiting CYP24A1 due to increased active vitamin D levels.Potential for nephrolithiasis with loss-of-function mutations in CYP24A1.Dysregulation may contribute to secondary hyperparathyroidism in CKD patients.
06

Interacting drugs

Calcitriol (active form of vitamin D)

2 more in the full profile.

07

Biomarkers

Serum levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin DParathyroid hormone (PTH)Fibroblast growth factor 23 (FGF23)Calcium/phosphate levelsGenetic variants in CYP27B1 or CYP24A1

Beyond the preview

Go deeper on Cytochrome P450 family 27 subfamily B member 1 (CYP27B1) and Cytochrome P450 family 24 subfamily A member 1 (CYP24A1) (CYP27B1 and CYP24A1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome P450 family 27 subfamily B member 1 (CYP27B1) and Cytochrome P450 family 24 subfamily A member 1 (CYP24A1) (CYP27B1 and CYP24A1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call